Mitochondrial ORF of Twelve S rRNA type-c
Evidence Grade C — Moderate human evidence. 230 published studies, 132 human. 3 registered clinical trials.
MOTS-c is a peptide encoded in the mitochondrial genome, discovered in 2015 as part of a newly identified class of mitochondrial-derived peptides. Research in animal models suggests effects on metabolic regulation. No human clinical trials have been conducted. The field is young and the science is still at an early stage.
230 published studies: 132 human, 48 animal, 28 in-vitro, 48 reviews
MOTS-c has no marketing authorisation. No human clinical trials have been conducted. The evidence base consists entirely of animal studies and cell culture experiments, primarily from the laboratory that discovered the peptide in 2015.
Human observational studies have reported correlations between circulating MOTS-c levels and metabolic parameters, but observational correlations do not establish therapeutic potential. The compound is of scientific interest as part of the emerging field of mitochondrial-derived peptides, but clinical translation has not been attempted. Products available through unregulated channels lack pharmaceutical quality assurance.
Research in animal models and cell culture suggests MOTS-c may interact with metabolic signalling pathways including AMPK activation. It was identified as a mitochondria-encoded signalling molecule, representing a novel form of communication between mitochondria and the cell nucleus. These observations are entirely preclinical.
Research in animal models and cell cultures suggests MOTS-c may interact with metabolic signalling pathways, particularly AMPK activation. Human observational studies have found correlations between circulating MOTS-c levels and metabolic parameters, but correlations do not establish therapeutic potential. No human clinical trials have been conducted. Most research originates from the laboratory that discovered the peptide. Independent replication is needed. The field of mitochondrial-derived peptides is young (since 2015), and MOTS-c's biological role and therapeutic relevance remain to be determined. Products from unregulated channels lack pharmaceutical quality assurance.
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
Cohort Of DEafness-gene Screening
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
